Rhumbline Advisers Has $636,000 Stake in Capricor Therapeutics Inc (NASDAQ:CAPR)

Rhumbline Advisers raised its position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) by 44.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,083 shares of the biotechnology company’s stock after acquiring an additional 14,169 shares during the quarter. Rhumbline Advisers owned about 0.10% of Capricor Therapeutics worth $636,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. SG Americas Securities LLC grew its stake in Capricor Therapeutics by 74.8% during the fourth quarter. SG Americas Securities LLC now owns 15,317 shares of the biotechnology company’s stock worth $211,000 after purchasing an additional 6,552 shares during the period. The Manufacturers Life Insurance Company bought a new position in shares of Capricor Therapeutics during the 3rd quarter worth approximately $161,000. Sassicaia Capital Advisers LLC acquired a new stake in shares of Capricor Therapeutics during the 3rd quarter worth approximately $192,000. Oppenheimer & Co. Inc. increased its stake in shares of Capricor Therapeutics by 25.2% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company’s stock valued at $1,040,000 after acquiring an additional 13,762 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of Capricor Therapeutics by 868.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock valued at $269,000 after acquiring an additional 15,872 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CAPR has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Tuesday. Cantor Fitzgerald increased their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Trading Down 5.7 %

CAPR opened at $12.81 on Friday. Capricor Therapeutics Inc has a 1-year low of $3.52 and a 1-year high of $23.40. The company has a market cap of $582.47 million, a price-to-earnings ratio of -12.08 and a beta of 4.08. The company’s fifty day moving average price is $14.37 and its two-hundred day moving average price is $13.92.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.